Top-News
Chemikalien Schweden

Orexo News

Aktie
WKN:  A0HG6G ISIN:  SE0000736415 US-Symbol:  ORXOF
1,817 €
+0,00 €
0,00%
18.05.24 13:03:47
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website

Orexo News

24.07.23 - PR Newswire
Orexo's patent win for ZUBSOLV® appealed
Orexo's patent win for ZUBSOLV® appealed PR Newswire
24.07.23 - PR Newswire
Orexo's patent win for ZUBSOLV® appealed
Orexo's patent win for ZUBSOLV® appealed PR Newswire
14.07.22 - PLX
Orexo Q2 EBIT SEK -49.7 Million
(PLX AI) – Orexo Q2 revenue SEK 147.8 million. • Q2 EBITDA SEK -32.5 million • Q2 EPS SEK -1.04
28.04.22 - PLX
Orexo Q1 EBIT SEK -13.2 Million
(PLX AI) – Orexo Q1 revenue SEK 159.4 million. • Q1 EBITDA SEK 2.8 million • Q1 EPS SEK -0.69
27.01.22 - PLX
Orexo Q4 EBIT SEK -64.1 Million vs. Estimate SEK -51 Million
(PLX AI) – Orexo Q4 revenue SEK 144 million vs. estimate SEK 140 million. • Q4 EBITDA SEK -48.5 million vs. estimate SEK -40 million • Q4 EPS SEK -1.92
16.11.21 - PLX
Orexo to File for OX124 FDA Approval; Sees U.S. Launch in H2 2023
(PLX AI) – Orexo pivotal trial OX124-002 meets the primary endpoints in the 4-period crossover, comparative bioavailability study in healthy volunteers. • OX124 showed a significantly ...
03.11.21 - PLX
Orexo Q3 EBIT SEK -59 Million
(PLX AI) – Orexo Q3 revenue SEK 145.9 million. • Q3 EBITDA SEK -47.4 million • Q3 EPS SEK -1.51
16.07.21 - PR Newswire
Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial
Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial The first cohort of healthy volunteers has been dosed. New Drug Application (NDA) filing expected in the ...
16.07.21 - PR Newswire
Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial
Orexo's flagship pharmaceutical pipeline asset OX124 enters pivotal trial The first cohort of healthy volunteers has been dosed. New Drug Application (NDA) filing expected in the ...
15.07.21 - PR Newswire
Orexo Q2 2021 Interim Report
Orexo Q2 2021 Interim Report PR Newswire
15.07.21 - PR Newswire
Orexo Q2 2021 Interim Report
Orexo Q2 2021 Interim Report PR Newswire
15.07.21 - PLX
Orexo Q2 EBIT SEK -54 Million vs. Estimate SEK -45 Million
(PLX AI) – Orexo Q2 revenue SEK 142.8 million vs. estimate SEK 151 million. • Q2 EBITDA SEK -41.1 million vs. estimate SEK -38 million • Q2 EPS SEK -2.15
12.07.21 - PR Newswire
Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis®
Orexo signs commercial partnership agreement with Sober Grid allowing community users access to clinically proven digital therapies vorvida® and deprexis® With more than ...
01.07.21 - PR Newswire
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD - The digital ...
01.07.21 - PR Newswire
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
Orexo announces first patient enrolled in pivotal study evaluating the efficacy of modia™ in combination with sublingual buprenorphine/ naloxone for the treatment of OUD - The digital ...
02.06.21 - PR Newswire
Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents
Orexo continues to strengthen ZUBSOLV´s patent portfolio with two new patents PR Newswire
29.04.21 - PR Newswire
Orexo Q1 2021 Interim Report
Orexo Q1 2021 Interim Report PR Newswire
29.04.21 - PR Newswire
Orexo Q1 2021 Interim Report
Orexo Q1 2021 Interim Report Investing in future growth drivers PR Newswire
23.03.21 - PR Newswire
Orexo publishes Annual Report for 2020
Orexo publishes Annual Report for 2020 PR Newswire
10.02.21 - PR Newswire
Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management
Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management PR Newswire

Newssuche

Videos

newspaper
17.05.24 +14,15%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »